Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-Enhanced BUCY vs Standard BUCY in High-Risk AML and MDS
NCT07183878Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Relapse-Free Survival at 24 months. Started Aug 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07183878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183878.